The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19
The EcoWeB research study, led by Professor Ed Watkins University of Exeter, seeks to understand what influences mood, how emotions change over time, and which emotional skills increase well-being among youth.
The participants are asked to use MyMoodCoach to monitor their emotions in daily life, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provide the participants with strategies to help them if they feel sad, stressed, anxious or have a problem. ‘Challenges’ help them to learn new skills, develop a positive mindset, improve their confidence and gain insight into their emotions.
The strong pick up of MyMoodCoach reflects a desire among youth to take better care of their mental wellbeing.
“We are very pleased to contribute to this project, as young people have been particularly impacted by COVID-19.” says Thomas Lethenborg, CEO of Monsenso. “Mobile health solutions have proved true value during the pandemic, allowing both clinical practice and important research projects to continue despite lockdowns.”
About the project:
The EcoWeB project is led by Professor Ed Watkins, University of Exeter, and involves 13 different institutions across 8 European nations (the UK, Germany, Belgium, Spain, Greece, the Czech Republic, Denmark, and Switzerland). The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754657.
About Monsenso digital health solution:
The Monsenso solution is a clinically-validated, CE Class I Marked mHealth solution classified as a Medical Device, consisting of a smartphone app for patients and clinical web portal for healthcare providers that is widely used in the prevention and treatment of common behavioural disorders such as depression and anxiety. It can also be configured to prevent and treat severe mental illnesses such as bipolar disorder, borderline personality disorder, PTSD and schizophrenia. It is currently being used by over 1,000 patients across the globe and is highly valued by patients and healthcare providers.